目的 分析生脉注射液对慢性淋巴细胞白血病患者血小板参数和患者外周血CD4+CD25+细胞水平的影响,以期探寻治疗慢性淋巴细胞白血病患者的最优方案.方法 选取衢州市人民医院2012年1月～2014年12月血液科收治的120例慢性淋巴细胞白血病患者为研究对象.对照组予CHOP方案:环磷酰胺600 mg/m2(d1),阿霉索25mg/m2(d12),长春新碱4mg(d1),泼尼松60mg/d(d1～5);28 d为1个疗程,共用4个疗程,观察组患者在对照组患者治疗的基础上联合生脉注射液,比较2组患者化疗效果、血小板参数以及血清CD4+CD25+T细胞和Th17细胞.结果 治疗后观察组患者PLT、MPV、PDW分别为(215.4±31.7)、(9.5±2.5)、(16.9±2.4),明显高于对照组患者;治疗后观察组患者CD4+CD25+T细胞为(1.5±0.8)低于对照组患者,Th17细胞为(3.9±1.2)明显高于对照组患者,差异有统计学意义(P<0.05);观察组60例患者CR29例、PR4例、NR27例,总有效率为55.0％,而对照组总有效率为35.0％,差异有统计学意义( P <0.05).结论 生脉注射液联合CHOP方案在慢性淋巴细胞白血病患者中运用有助于改善患者免疫功能,促进血小板增长,改善血小板各临床参数,而且有助于改善患者化疗有效率,相比单用CHOP方案治疗效果更好,值得临床推广运用.
Effects of Shengmai injection on platelet parameters and CD4+CD25+T cells in patients with chronic lymphocytic leukemia
Objective To study the effect of Shengmai injection on the platelet parameters and CD4+CD25+cells in peripheral blood of patients with chronic lymphocytic leukemia,and to explore the optimal regimen for patients with chronic lymphocytic leukemia.Methods One hundred and twenty patients with chronic lymphocytic leukemia were enrolled in this study from January 2012 to December 2014.(D1),vincristine 4mg(d1),prednisone 60 mg/d(d1-5)were given to the CHOP regimen in the control group: cyclophosphamide 600 mg/m2(d1),doxorubicin 25 mg/m2(d12)28d a course of treatment,a total of 4 courses,the observation group of patients in the control group of patients treated on the basis of Shengmai injection,compared the two groups of patients with chemotherapy,platelet parameters and serum CD4+CD25+T cells and Th17 cells.Results After treatment,the PLT,MPV and PDW of the observation group were(215.4± 31.7),(9.5±2.5)and(16.9±2.4),respectively,which were significantly higher than those of the control group.The CD4+CD25+T cells in the observation group were(1.5±0.8)The total effective rate of the control group was 35.0％,the total effective rate was 35.0％,and the total effective rate of the control group was 35.0％.There were significant difference between the control group and the control group(P<0.05),The difference was statistically significant.Conclusion Shengmai injection combined with CHOP regimen in chronic lymphocytic leukemia patients can improve immune function,promote platelet growth,improve platelet clinical parameters,and help improve the efficiency of chemotherapy,compared with CHOP alone Program treatment is better,worthy of clinical application.
NETL
NSTL
万方数据
